Keros Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Keros Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Keros is positioned as an attractive clinical-stage biotech with near-term catalysts in DMD and neuromuscular disease, supported by improved cash flow and analyst support. Keros has a Buy consensus rating from 7 analysts as of February 17, 2026. The company plans to initiate a Phase 2 clinical trial of.
What is Keros Therapeutics, Inc.'s industry? Keros Therapeutics, Inc. (kerostx.com) operates in Biopharmaceutical / Clinical-Stage Therapeutics. AskCyborg classifies Keros Therapeutics, Inc. under Biopharmaceutical / Clinical-Stage Therapeutics in its company registry.
Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. T...
Cyborg Score thesis
Keros is positioned as an attractive clinical-stage biotech with near-term catalysts in DMD and neuromuscular disease, supported...
Read the full analyst-debate transcript →Get the Latest Keros Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeKeros Therapeutics, Inc. Overview
Pro stress-test →Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics for patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. The company is a leader in understanding TGF-ß proteins, which are master regulators of growth, repair and maintenance of tissues including blood, bone, skeletal muscle, adipose and heart tissue.
Strategic Profile
Pro stress-test →Keros' lead product candidate is rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, while its most advanced product candidate, elritercept, is being developed for cytopenias in myelodysplastic syndrome and myelofibrosis patients. The company posted a net loss of $7.3 million in Q3 2025 versus $53.0 million in Q3 2024, driven by revenue recognized under its license agreement with Takeda.
Competitive Landscape
Pro stress-test →The DMD space is particularly competitive and complex; many patients are treated with corticosteroids, and Sarepta Therapeutics is a formidable competitor with exon-skipping therapies including Exondys 51, Vyondys 53 and Amondys 45. The company faces increased competition from both established and emerging therapies that could dilute market share.
Industry Context
Keros Therapeutics, Inc. operates in Biopharmaceutical / Clinical-Stage Therapeutics.
Key facts
Founded: 2015 · Headquarters: Lexington, Massachusetts, US · Market cap: $620.3M